It has expanded its pipeline with Enriched Tear Film (ETF) Gene Therapy, OC-101. Preclinical research has shown 42-day proof-of-concept in vivo ...
https://www.google.com/url?rct=j&sa=t&url=https://www.biospace.com/article/oyster-point-pharma-inks-deal-with-ji-xing-for-dry-eye-disease-therapies/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEqFPvC49vs1yVt7c3fmob5QlrgiA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.